Therefore, our data further corroborate the notion that tumor-associated ECFCs are insensitive to VEGF and lend the first strong cellular and molecular support to the notion that VEGFR2 is unlikely to be the most suitable target to halt vascularization and prevent tumor relapse in BC patients. The gene discussed is KDR; the disease is neoplasm.